Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Jianghua Ding"'
Autor:
Jianghua Ding, Shengping Gong
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/1224ecc4e3ad4f689992c19b5f4dcdc4
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Breast cancer is the most common malignant tumor in women, posing a serious threat to women’s health. HER2 has been identified as a key oncogene and prognostic factor in breast cancer. Recent studies have reported inconsistencies in ER, PR, and/or
Externí odkaz:
https://doaj.org/article/49111d4624924194ad735c19befcc06c
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
The third-generation EGFR-TKIs, such as osimertinib, aumolertinib, and furmonertinib, have been recommended as the preferred treatment for EGFR-mutant advanced non-small cell lung cancer (NSCLC). Among them, furmonertinib shows several advantages in
Externí odkaz:
https://doaj.org/article/aee6fb540f7748f78ce0492b98f9a1a8
Publikováno v:
Materials Today Bio, Vol 24, Iss , Pp 100913- (2024)
Cancer has become an increasingly important public health issue owing to its high morbidity and mortality rates. Although traditional treatment methods are relatively effective, they have limitations such as highly toxic side effects, easy drug resis
Externí odkaz:
https://doaj.org/article/05661e16c0504cbfa85e2519231d8a59
Autor:
Yan Chen, Ruibin Huang, Jianghua Ding, Dexiang Ji, Bing Song, Liya Yuan, Hong Chang, Guoan Chen
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-3 (2023)
Externí odkaz:
https://doaj.org/article/9f0f85c5efca4e51ae3972f48eea6450
Autor:
Jianghua Ding, Wen Li
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: The advent of first- and second-generation BCR/ABL1 tyrosine kinase inhibitors (TKIs), such as imatinib and dasatinib, has markedly improved the clinical outcomes of patients with philadelphia chromosome–positive acute lymphoblastic leu
Externí odkaz:
https://doaj.org/article/5a7d65568d214045b429d0c3f0e0a540
Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The phenomenon of histological transformation has been widely reported in advanced non-small cell lung cancer (NSCLC) with EGFR mutations following the failure of EGFR-TKI treatment. Recent evidence suggests that similar histological changes can also
Externí odkaz:
https://doaj.org/article/b7e51e8e41d54416ab3010b5ebe5e5a4
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ObjectiveThe histological conversion of lung adenocarcinoma (LUAD) into small-cell lung cancer (SCLC) is an important resistance mechanism for epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-resistant LUAD. Anlotinib has been
Externí odkaz:
https://doaj.org/article/597b05ad5a0143df8dca6857614a8aad
Autor:
Cong Shi, Shengping Gong, An Wu, Shujun Yang, Duobing Zou, Yi Zhang, Ningning Wu, Chao Ma, Songqiu Shi, Ying Chen, Ying Wu, Xiaojiao Zheng, Zhenya Huang, Jianghua Ding, Guifang Ouyang, Qitian Mu
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Myelodysplastic syndromes (MDS) is a group of heterogeneous myeloid clonal diseases originating from hematopoietic stem cells. It has been demonstrated that apolipoproteins A1(ApoA1) are associated with disease risk in many cancer
Externí odkaz:
https://doaj.org/article/36972b8131a54d88b372f8333083bc01
Autor:
Yan Chen, Ruibin Huang, Jianghua Ding, Dexiang Ji, Bing Song, Liya Yuan, Hong Chang, Guoan Chen
Publikováno v:
Scientific Reports, Vol 5, Iss 1, Pp 1-8 (2015)
Abstract Multiple myeloma (MM) was characterized by frequent mutations in KRAS/NRAS/BRAF within the EGFR pathway that could induce resistance to EGFR inhibitors. We here report that EGFR inhibition solely exhibited moderate inhibition in KRAS/NRAS/BR
Externí odkaz:
https://doaj.org/article/861aae3bc66b46a283d2cae15d1e172d